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a  b  s  t  r  a  c  t
To determine the epidemiological and molecular characteristics of 12 Staphylococcus aureus
isolates presenting heteroresistance to vancomycin in laboratories of two cities in Santa
Catarina, southern Brazil. Epidemiological data, including the city of isolation, health insti-
tution, and date of isolation were considered, as well as the associated clinical specimen. For
molecular characterization, we analyzed the staphylococcal cassette chromosome types,
the  erm gene presence, and the genomic diversity of isolates using pulsed-ﬁeld gel elec-
trophoresis. The 12 isolates of S. aureus were previously conﬁrmed as heteroresistance to
vancomycin using the population analysis proﬁle–area under curve. Regarding genetic vari-
ability, two clones were detected: the main one (clone A) composed of four isolates and the
clones B, with two isolates. For clone A, two isolates presented identical band patterns and
were  related to the same hospital, with an interval of 57 days between their isolation. The
other isolates of this clone showed no epidemiological link between them because they were
isolated in different hospitals and had no temporal relationship. The other clone showed
no  detectable epidemiological relationship. The heteroresistance to vancomycin recovered
in  Santa Catarina State from 2009 to 2012 had, in general, heterogeneous genomic pat-
terns  based on pulsed-ﬁeld gel electrophoresis results, which is in accordance with the fact
that  these isolates had little or no epidemiological relationship among them. Due to the
characteristic phenotypic instability and often prolonged vancomycin therapy for selection,clonal spread is not as common as for other resistance mechanisms disseminated through
horizontal gene transfer.
© 2015 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
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ntroduction
taphylococcus aureus can acquire, during prolonged ther-
py with glycopeptides, a very peculiar resistant phenotype.
hrough selective pressure and apparently without trans-
er of genetic material, it may undergo mutations in genes
esponsible for cell wall production, making it thicker and less
usceptible to the action of antimicrobials.1
The heteroresistance of S. aureus to vancomycin (hVISA)
auses changes in the macro-morphological features of the
olonies, that present with heterogeneous appearance and
igmentation, giving the impression of contamination and
ay confuse the microbiologist.2 Its mechanism of resis-
ance is associated with activation of cell wall synthesis,
hich increases the production of waste mucopeptide and
educes the amount of antibiotic that reaches the site of
ction, thus causing cell wall thickening and subsequent drug
mprisonment.3 Speculation that hVISA could be regarded as
recursors of VISA strains once, after prolonged exposure to
ntimicrobial could select a homogenous population of cells
xpressing the phenotype VISA. This phenotype is unstable.4
The detection of infections caused by hVISA represents a
hallenge for microbiologists, since these strains are consid-
red susceptible to vancomycin in vitro (minimum inhibitory
oncentration (MIC) ≤2 g/mL), and therefore categorized as
usceptible by the usual laboratory methods.1 However, as it
ontains subpopulations 1 in each 106 bacterial cells, that can
row in the presence of 4 g/mL of vancomycin, it may lead to
reatment failure5,6 with vancomycin,.
Reference methods used to evaluate susceptibility as
roth microdilution, Etest and automated methods fail to
etect hVISA. Because the phenotype is a heterogeneous
henomenon, reliable molecular markers to conﬁrm this phe-
otype have not yet been found. Partly due to the small
noculum, relatively poor growth on Mueller-Hinton agar, or
ncubation for only 24 h. The inoculum size is critical to the
etection of subpopulation of resistant cells; furthermore
VISA strains are notoriously slow growing, with cell walls
hicker and pleomorphic unique characteristics, with colonies
f varying sizes and nutritionally exacting.7
The population analysis proﬁle–area under the curve
PAP–AUC) has been the most reliable and reproducible
pproach, being considered the gold-standard test for hVISA.8
t was speciﬁcally designed for discriminating hVISA and
ISA. It is a method of analysis of modiﬁed sub-populations
sing serial concentrations of vancomycin, in order to quan-
ify the viable bacterial populations in such concentrations. It
s a very laborious, expensive, and inappropriate for routine
se in clinical laboratories.9
In a meta-analysis published in 2011, the rates of treat-
ent failure (designated as persistent infection or bacteremia)
elated to hVISA isolates were two times more  common than
n infections caused by S. aureus susceptible to vancomycin
OR: 2.37, 95% CI: 1.53–3.67).6 Therefore, an accurate and prac-
ical laboratory method for the detection of hVISA isolated in
linical practice is of increasing importance.10Despite the controversy between studies regarding the
ssociation of hVISA and mortality, knowledge of the epi-
emiological proﬁle is very important in assisting the clinician5;1 9(5):466–472 467
when choosing the appropriate antibacterial therapy. The
objective of this study was to evaluate the phenotypic and
molecular epidemiology characteristics of hVISA isolates in
the state of Santa Catarina, Brazil.
Methods
Bacterial  samples
We  used 12 clinical isolates of hVISA obtained from various
anatomical sites of patients in hospitals in Florianópolis and
hospital in Blumenau, all located in the state of Santa Catarina
in southern Brazil. Samples were collected from November
2009 to October 2012.
Antimicrobial  susceptibility  testing
Antimicrobial susceptibility testing was performed using the
disk diffusion method, according to the recommendations and
interpretive criteria of the Clinical and Laboratory Standards
Institute.11 We  also performed the D test for the detection
of inducible resistance to clindamycin. Disks of erythromycin
and clindamycin were placed 26 mm apart, and a ﬂattening
of the inhibition zone indicated a positive test, which was
reported as clindamycin resistance. Vancomycin MICs were
determined by macrodilution method.11
PAP–AUC
After incubation on solid medium, the bacteria were diluted
in sterile saline at dilutions ranging from 10−1 to 10−8 and
subsequently spotted as 10-L spots on BHI agar plates con-
taining 0, 0.5, 1, 2, 3, 4, 5, 6 and 8 g/mL of vancomycin.
The plates were incubated for 48 h, and the colonies were
counted to determine the log10 CFU/mL; these data were then
plotted on a graph as a function of the vancomycin concen-
tration. The AUC was calculated using the strain Mu3  (ATCC
700698) as a control. To conﬁrm the designation as hVISA,
the ratio of the AUC of the isolate to that of the Mu3  strain
must be greater or equal to 0.9 and non-hVISA isolates had a
PAP–AUC < 0.9.7,8
Multiplex  PCR  for  the  detection  of  the  staphylococcal
cassette  chromosome  (SCCmec)
The SCCmec type was determined using the multiplex PCR
method according to the protocol developed by Zhang et al.
The amplicons that were formed had the following sizes: I
(613 bp), II (398 bp), III (280 bp), IVa (776 bp), IVb (493 bp), IVc
(200 bp), IVd (881 bp), and V (325 bp).12,13
PCR  for  erm  gene  detection
For isolates with positive results in the phenotypic test for
inducible resistance to clindamycin, erm gene PCR ampliﬁca-
tion was performed according to the multiplex PCR protocol
developed by Khan et al.14 The PCR products (610 bp for ermA
and 520 bp for ermC) were analyzed by electrophoresis through
a 1.5% agarose gel.14,15



















































































Fig. 1 – Growth curves of the twelve isolates characterized as hVISA compared to the standard strain Mu3. All isolates
showed an AUC/Mu3 AUC ratio greater than 0.9. For clarity, bacterial growth was expressed in log10 CFU/mL. Nine
concentrations of vancomycin (0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 and 8 g/mL) were  used. Graph A depicts isolates S4, S11 and
S13. Graph B shows isolates L10, L43 and L36. Graph C shows isolates L54, L69 and L74. Graph D shows isolates L80, L84
and L92. The reference strain Mu3  is shown in all graphs.Pulsed-ﬁeld  gel  electrophoresis  (PFGE)
PFGE was performed according to McDougal et al.16 and Pinto
et al.17 The fragments were subjected to PFGE using 1% agarose
gels (Pulsed Field Certiﬁed Agarose; Bio-Rad) in 0.5× Tris-
borate-EDTA buffer with a CHEF-DR III system (Bio-Rad). The
gels were stained with 0.5 g/mL ethidium bromide, visual-
ized under UV light, and photographed using a GelDocTM XR
System (Bio Rad). The PFGE patterns were analyzed using
Bionumerics version 6.1 (Applied Maths, Sint-Martens-Latem,
Belgium). The PFGE patterns were clustered by UPGMA. A den-
drogram was generated from a similarity matrix calculated
using the Dice similarity coefﬁcient with an optimization of
0.5% and a tolerance of 1%. PFGE clusters were deﬁned as iso-
lates with a similarity of 80% or higher on the dendrogram.18
Results
The twelve hVISA isolates were recovered from tracheal aspi-
rates (n = 5), osteomyelitis (n = 4), blood (n = 1), skin lesion (n = 1),
and surgical wound (n = 1). Resistance of the 12 hVISA iso-
lates to antimicrobial agents was assessed by disk diffusion,
with the following results: clindamycin (92.7%), erythromycin
(100%), trimethoprim/sulfamethoxazole (16.7%), ciproﬂoxacin
(92.7%), tetracycline (16.7%), chloramphenicol (8.3%), and gen-
tamicin (33.3%). All isolates were considered susceptibleto linezolid and teicoplanin. The vancomycin MICs were
1.0 g/mL (33.3%) and 2.0 g/mL (66.7%) (Fig. 1).
Only two isolates (10 and 54) exhibited inducible clin-
damycin resistance, as determined by a positive D test. These
isolates were subjected to PCR for erm gene detection, and both
contained the ermA gene. Isolate 84, which was resistant to
erythromycin and sensitive to clindamycin, yielded a negative
D test, and the erm gene was not ampliﬁed. All other isolates
showed constitutive clindamycin resistance.
Isolate SI4 contained two SCCmec types (I and II). Isolate
84 contained SCCmec type I. Isolates S11, 36, 54, 69, 80 and
92 contained SCCmec type II. SCCmec type III was observed
in isolates SI13, 10 and 43. Although isolate 80 was consid-
ered to be a community isolate, it did not contain SCCmec type
IV, which is frequently associated with community-acquired
methicillin-resistant S. aureus (CA-MRSA). Only the isolate 74
showed SCCmec type IV (IVc). The isolation of the microorgan-
ism in the ﬁrst 48 h of admission was used as the criterion for
classiﬁcation as CA-MRSA.
PFGE was used to assess the degree of genetic similar-
ity, and the results are presented in Fig. 2. Two clones were
observed: a primary clone (A), comprising four isolates (SI4,
L54, L69, and L92); and clone B, comprising isolates L36 and
L80. Isolates SI11, SI13, L10, L43, L74, and L84 did not display
genetic similarity with any of the other isolates. The crite-
ria established by Tenover were used for classiﬁcation, with
a similarity index of 80%.
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Fig. 2 – Dendrogram showing the similarities between the 12 hVISA isolates. Two clones were  observed: one comprising
four isolates (A), two of which displayed 100% similarity (L54 and L69); and clone B, which comprised two isolates that were










In addition to the molecular characteristics described
bove, Table 1 presents the city of isolation, attended insti-
ution, biological sample, and isolation date. The samples
ere isolated in two different cities that are 120 km apart. In
he city of Florianópolis, the state capital of Santa Catarina,
hree hospitals and two clinics were included. Approximately
3 months separated the ﬁrst and last isolates. Isolates L54
nd L69 were isolated in the same hospital, had 100% genetic
imilarity, and were isolated from patients with osteomyelitis
Table 1 – Epidemiological and clinical characteristics of the 12 h
Isolate number City Institution Clinic
10 Florianópolis Hospital A Osteom
36 Florianópolis Hospital A Trache
43 Florianópolis Hospital A Surgica
54 Florianópolis Hospital A Osteom
69 Florianópolis Hospital A Osteom
74 Florianópolis Hospital B Skin le
80 Florianópolis Clinic A Trache
84 Florianópolis Hospital A Trache
92 Florianópolis Hospital C Trache
SI4 Blumenau Hospital D Blood 
SI11 Blumenau Hospital D Trache
SI13 Blumenau Hospital D Osteomapproximately 57 days apart, which might indicate a common
route of infection.
DiscussionAs far as we know, this is the ﬁrst description of hVISA in
Brazil. Two Brazilian studies reported decreased susceptibility
to vancomycin, but have not conﬁrmed hVISA phenotype. In
VISA isolates.
al sample SCCmec Clone Date
yelitis III Non clonal 23/11/2009
al aspirate II B 03/09/2010
l wound III Non clonal 14/10/2010
yelitis II A 04/05/2011
yelitis II A 01/07/2011
sion IVc Non clonal 22/12/2011
al aspirate II B 09/01/2012
al aspirate I Non clonal 25/02/2012
al aspirate II A 18/08/2012
I,II A 28/09/2010
al aspirate II Non clonal 20/02/2011
yelitis III Non clonal 12/04/2011
i s . 2 0
r470  b r a z j i n f e c t d 
2001, Oliveira and colleagues reported ﬁve clinical isolates of
MRSA with MIC  of 8 g/mL, which were named VRSA, based on
available criteria (NCCLS-1997). However, the isolates did not
harbor Van genes and, as previously demonstrated by other
authors, presented a cell wall thickening.19 In 2006, Lutz and
Barth described 18 clinical isolates as possible hVISA, since
they were positive for screening test (BHI with 4 g/mL of van-
comycin). However, the PAP–AUC conﬁrmatory test for hVISA
was not performed, especially because, on that time, the cur-
rent accepted criteria for conﬁrmation of this phenotype were
not known.20,21 Based on these data, we  believe our study pro-
vides the ﬁrst report of hVISA isolation in Brazil.
The most frequently anatomical sites associated with
hVISA infections are those with a higher bacterial inoculum
(abscesses, pneumonia) and those associated with chronic
infections (endocarditis, osteomyelitis) for which the use of
vancomycin for prolonged periods is quite common and the
low penetration of the antibiotic in these sites favors the devel-
opment of resistance.7 Several studies3,22–25 have established
that blood, lower respiratory tract, skin wounds, abscesses and
osteomyelitis are the most common sites of hVISA isolation.
These ﬁndings are similar to those of the present study.
The isolates exhibited a proﬁle of heterogeneous suscepti-
bility, characterized by low resistance to chloramphenicol and
trimethoprim/sulfamethoxazole, drugs that are used infre-
quently to treat MRSA infections. Other studies22,24 have
reported low rates of resistance to sulfonamides in hVISA iso-
lates, ranging from 9 to 9.9%. By contrast, studies of samples
from Korea26 and China23 revealed much higher values, 58 and
54%, respectively. A chloramphenicol resistance rate of 16.7%
was observed in our study, while Hu and colleagues observed
a rate of 47.6% in 2013.23 Resistance rates to macrolides,
lincosamides, aminoglycosides, ﬂuoroquinolones, and tetra-
cyclines are high, with values greater than 64%, precluding
its empirical use.22–24,26 Knowledge of the local susceptibility
proﬁle is essential for adequate empirical therapy.
Clindamycin is a therapeutic option for the treatment
of serious infections caused by S. aureus,  including MRSA,
particularly for isolates with SCCmec type IV, which usually
are resistant only to beta-lactams.27 However, one common
mechanism of resistance is the macrolide-lincosamide-
streptogramin B (MLSB) phenotype, which expresses inducible
clindamycin resistance, which cannot be detected by tradi-
tional phenotypic tests and requires the D test.28 In our study,
two isolates exhibited inducible clindamycin resistance, and
both possessed the ermA gene. Both were reported to be resis-
tant to clindamycin, and thus inappropriate treatment was
avoided.
There was a predominance of SCCmec  type II, which is asso-
ciated with hVISA; in MRSA, this type is associated with higher
mortality rates.23 Other studies have also demonstrated a pre-
dominance of SCCmec type II among hVISA isolates.22,23,29,30
Some studies have demonstrated a predominance of other
types of SCCmec  between hVISA isolates such as type I31 and
type III.32–34 It is interesting to note that among the 12 isolates,
only one had SCCmec  type IV (IVc). Although some studies did
31,34not ﬁnd type IV SCCmec among their MRSA isolates, others
demonstrated rates as high as 16.8%22 to 26.3%.32
From an epidemiological perspective, it is difﬁcult to per-
form further analyses due to the geographical distance and the 1 5;1  9(5):466–472
time interval between the isolation of the ﬁrst and last isolates.
The microorganisms were isolated over a period of three years
in different cities and even in several different institutions in
the city of Florianópolis. Except for isolates L54 and L69, which
are the same clone and were isolated in the same institution,
the hVISA isolates did not have any characteristics that would
enable an epidemiological link to be made between them.
The hVISA recovered in Santa Catarina State from 2009 to
2012 had, in general, heterogeneous genomic patterns accord-
ing to the PFGE results, which is in accordance with the fact
that these isolates had little or no epidemiological relationship
among them.
It should be noted that due to its continental dimen-
sions and tourist vocation, Brazil presents a great diversity of
resistance mechanisms, and S. aureus with resistance to van-
comycin (VRSA) was ﬁrst described in 2014 in South America.35
This fact demonstrates the real need for the surveillance of
bacterial resistance in our country.
Epidemiological information from each health facility, as
well as each geographical region, is critical to the implemen-
tation of appropriate empirical therapy, especially with regard
to hVISA isolates. Such bacteria have phenotypic characteris-
tics that are difﬁcult to be correctly identify by conventional
methods (MIC determination and molecular tests) and are
associated with worse clinical outcomes. Due to the charac-
teristic instability phenotype and often prolonged vancomycin
therapy for selection, clonal spread is not as common as for
other resistance mechanisms disseminated through horizon-
tal gene transfer.
It is imperative that clinical microbiology laboratories
detect the hVISA phenotype and associate it with the epi-
demiological characteristics of the patients (e.g., age, date of
isolation, anatomical site, prior use of vancomycin) to provide
important information for research laboratories. Through
appropriate methodologies, associations between the micro-
biological data and the clinical characteristics of patients may
enable the detection of possible associated risk factors and aid
in assessing the prognosis of patients.
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